Non-small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Hamamatsu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age equal to or more than 20 years at the time of study entry 2. Locally advanced, recurrent, or metastatic non-small cell lung cancer without druggable driver genetic alterations assessed by multiplex companion diagnostics 3. Standard treatment has been completed or is expected to be completed 4. Comprehensive genomic profiling tests are planned 5. Written informed consent obtained from the subject
Exclusion criteria
Exclusion criteria: 1. Patients who do not meet the insurance coverage of the National Health Insurance in Japan for comprehensive genomic profiling testing 2. Patients with driver genetic alterations that are druggable by approved agents determined by multiplex companion diagnostics at the time of diagnosis 3. Patients who received more than one line of systemic treatment after the completion of standard treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with actionable cancer genomic alterations detected using comprehensive genomic profiling tests. | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients with options of molecular-based recommended therapy (MBRT) determined by the molecular tumor board. The proportion of patients with druggable genomic alterations. The proportion of patients who received MBRT including clinical trials. The success rate of the comprehensive genomic profiling tests. Matching score of MBRT calculated using a matching score system. Response rate and progression-free survival in the treatment after comprehensive genomic profiling. Overall survival. Progression-free survival in MBRT. | — |
Countries
Japan
Contacts
Public ContactYusuke Inoue
Hamamatsu University School of Medicine Second Division, Department of Internal Medicine
Outcome results
None listed